Entecavir versus tenofovir in patients with chronic hepatitis b: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee; Jonggi Choi; Seung Up Kim; Young Suk Lim

doi:10.3350/cmh.2021.0179

Entecavir versus tenofovir in patients with chronic hepatitis b: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee
, Jonggi Choi
, Seung Up Kim
, Young Suk Lim

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.

Original language	English
Journal	Clinical and Molecular Hepatology
Volume	27
Issue number	3
DOIs	https://doi.org/10.3350/cmh.2021.0179
State	Published - Jul 2021

Bibliographical note

Publisher Copyright:
© 2021 by Korean Association for the Study of the Liver.

Keywords

Carcinoma
Efficacy
Entecavir
Hepatitis B
Hepatocellular
Outcome
Tenofovir

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3350/cmh.2021.0179

Cite this

@article{ace9526d657e499b9086011f407ba6f5,

title = "Entecavir versus tenofovir in patients with chronic hepatitis b: Enemies or partners in the prevention of hepatocellular carcinoma",

abstract = "Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.",

keywords = "Carcinoma, Efficacy, Entecavir, Hepatitis B, Hepatocellular, Outcome, Tenofovir",

author = "Lee, \{Sung Won\} and Jonggi Choi and Kim, \{Seung Up\} and Lim, \{Young Suk\}",

note = "Publisher Copyright: {\textcopyright} 2021 by Korean Association for the Study of the Liver.",

year = "2021",

month = jul,

doi = "10.3350/cmh.2021.0179",

language = "English",

volume = "27",

journal = "Clinical and Molecular Hepatology",

issn = "2287-2728",

publisher = "Korean Association for the Study of the Liver",

number = "3",

}

TY - JOUR

T1 - Entecavir versus tenofovir in patients with chronic hepatitis b

T2 - Enemies or partners in the prevention of hepatocellular carcinoma

AU - Lee, Sung Won

AU - Choi, Jonggi

AU - Kim, Seung Up

AU - Lim, Young Suk

PY - 2021/7

Y1 - 2021/7

N2 - Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.

AB - Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.

KW - Carcinoma

KW - Efficacy

KW - Entecavir

KW - Hepatitis B

KW - Hepatocellular

KW - Outcome

KW - Tenofovir

UR - https://www.scopus.com/pages/publications/85110089866

U2 - 10.3350/cmh.2021.0179

DO - 10.3350/cmh.2021.0179

M3 - Article

C2 - 34157830

AN - SCOPUS:85110089866

SN - 2287-2728

VL - 27

JO - Clinical and Molecular Hepatology

JF - Clinical and Molecular Hepatology

IS - 3

ER -

Entecavir versus tenofovir in patients with chronic hepatitis b: Enemies or partners in the prevention of hepatocellular carcinoma

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this